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Abstract 
 Diets rich in fruits and vegetables have been correlated to lower disease risk. This is 
theorized to be due to food bioactive components such as: vitamin C, vitamin E, carotenoids, and 
polyphenols. Polyphenols are of particular interest in dietary research do to their abundance in the 
human diet. The effects of whole grapes, in the form of a standardized, freeze-dried grape powder 
(GRAPE) were tested in adults with metabolic syndrome (MetS).   
Subjects entered a randomized, placebo-controlled, crossover intervention for 13 weeks. 
This included a 2-week run-in, 4-week intervention (GRAPE or placebo), 3-week washout, and 
final 4-week intervention (alternate powder).  Qualifying subjects (n = 20; 12 male, 8 female) were 
instructed to consume 60 g/day of GRAPE or nutritionally matched placebo. Subjects were 
consuming the equivalent of 2.5 cups of fresh grapes a day, which contains roughly 200 mg of 
polyphenols. The placebo did not contain polyphenols found in grapes. Subjects did not 
significantly alter their diets when comparing GRAPE and placebo.  
The first aim of the study examined the effect of GRAPE on cardiometabolic risk factors. 
Plasma lipids, glucose, and alanine aminotransferase (ALT) were not significantly different 
between GRAPE and placebo periods. Interestingly, GRAPE slightly, but significantly, decreased 
BMI compared to placebo (-0.22 kg/m2, p = 0.048). Additionally, a trend in weight reduction was 
apparent in the GRAPE group (-0.62 kg, p = 0.081). When stratifying for sex, plasma triglycerides 
(TG) (-43.45 mg/dL, p = 0.033) and pulse (-3.94 bpm, p = 0.003) were significantly reduced in 
men. In the female group a significant increase in TC was observed (5.25 mg/dL, p = 0.003) as 
well as Non-HDL-C (7.50 mg/dL, p = 0.010) with GRAPE ingestion compared to placebo.  
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The second aim of the study examined the effects of GRAPE on oxidative stress, 
inflammation and insulin resistance. Markers of oxidative stress, measured as advanced oxidative 
protein products (AOPPs), or thiobarbituric acid reactive substances (TBARS), were unaltered 
when comparing GRAPE to placebo. Plasma cytokines TNF-α, IL-6, and MCP-1 did not change 
significantly when comparing GRAPE to placebo. Finally, when examining plasma insulin 
changes and HOMA insulin resistance score, no significant differences were seen between groups. 
However, when stratifying for sex, significant differences were seen in the female subset. Plasma 
AOPPs were seen to be trending toward a significant increase compared to placebo (-24.35 µM 
vs, p = 0.085). Plasma TBARS were significantly increased with GRAPE compared to placebo (-
0.19 µM, p = 0.042). It was seen that GRAPE significantly increased plasma insulin (9.82 ± 3.94 
pmol/L, p = 0.042) and HOMA-IR Score (0.40 ± 0.16, p = 0.043) in the female subset. 
These results suggest that GRAPE may influence body weight or composition, but not 
plasma lipids or underlying comorbidities, in a mixed sex population of adults with MetS. Further 
research is warranted on sex-dependent effects. 
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Introduction 
 In 2012, roughly 39 million people died from non-communicable, chronic, yet preventable, 
diseases (World Health Organization, 2015). The four main diseases were: diabetes, cancer, 
chronic lung disease, and cardiovascular disease (CVD). Throughout the world, CVD alone 
claimed 17.5 million lives in 2012, amounting to 30% of total deaths. Another chronic condition 
which warrants concern is type 2 diabetes mellitus (T2DM). Recent research estimates 9.3% of 
individuals in the United States are afflicted with T2DM, and more noteworthy, it is frequently 
listed as a cause of death (American Diabetes Association, 2017). However, in 2010, roughly only 
35 to 40% of deaths of Americans with diabetes mentioned it on the death certificate. This suggests 
that diabetes may be an underreported cause of death. Interestingly, some of the identified risk 
factors for CVD overlap with those of T2DM, which has led to the recognition of metabolic 
syndrome (MetS) (National Institutes of Health, National Heart, Lung, and Blood Institute, 2016).  
Metabolic syndrome is a constellation of symptoms that together, increases the risk for 
development of T2DM and CVD. 
 The symptoms of MetS include: decreased concentrations of high-density lipoprotein 
cholesterol (HDL-C), and elevated plasma triglycerides (TG), fasting blood glucose, systolic blood 
pressure (SBP) or diastolic blood pressure (DBP), and elevated waist circumference (WC). Having 
three of the five previously mentioned symptoms qualifies an individual as having MetS (National 
Institutes of Health, National Heart, Lung, and Blood Institute, 2016).  
In a state of high plasma FFA or TG, which can be present in excess central adiposity 
characteristic of MetS, the excess may be redirected to non-adipose tissues. Hepatic uptake of FFA 
is unregulated. If circulating levels of FFA are high, the liver will take them into its cells (Malhi 
and Gores, 2008). In the fatty liver, circulating FFA can activate many intracellular responses such 
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as: C-jun N-terninal kinase (JNK) activation, toll-like receptor (TLR) activation, and endoplasmic 
reticulum (ER) stress. The downstream result of these activations is insulin resistance (Shoelson, 
2006). Additionally, the activity of tumor necrosis factor (TNF)-α increases the release of FFA 
from adipocytes and blocks the synthesis of adiponectin, which sensitizes adipose tissue to insulin. 
TNF-α also can activate NF-κB signal transduction, leading to the production of cellular adhesion 
molecules, and an inflammatory state in the adipocyte (Fernandez-Sanchez et al., 2011). It can 
also stimulate the expression of IL-6 and MCP-1 (Kern et al., 2001) These molecules attract 
inflammatory cells to the afflicted area, which generates a larger inflammatory response. 
Inflammation is not the sole contributor to insulin resistance. Oxidative stress can result in the 
dysfunction of insulin-related pathways (Keane et al., 2015). Excessive generation of reactive 
oxygen species (ROS) can lead to the damage of DNA, protein, and lipid membranes. Oxidative 
stress via ROS can be the result of over nutrition in the form of high glucose and lipid diets (Keane 
et al., 2015). This over nutrition can lead to the dysfunction of the electron transport chain, which 
produces increased ROS. Another pathway that ROS may be generated is via superoxide 
dismutase. Superoxide can be converted to H2O2, which is much more stable. However, H2O2 itself 
can react with Fe2+ to produce a highly reactive hydroxyl radical (OH•) (Keane et al., 2015). The 
consequences of all this damage is ultimately cell death and an inflammatory response. 
Insulin resistance, inflammation, and oxidative stress are states commonly associated with 
MetS however, MetS is preventable by lifestyle interventions such as smoking cessation, 
increasing exercise, or modifying diet (National Institutes of Health, National Heart, Lung, and 
Blood Institute, 2016). 
Disease prevention through dietary modifications is of particular interest. Data has shown 
that increased consumption of fruit and vegetables is correlated with reduced risk for all-cause 
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mortality and CVD (Wang et al., 2014). This appears to be due to the bioactive components of 
these foods, such as vitamin C, vitamin E, carotenoids, and polyphenols (Perez-Jimenez and Saura-
Calixto, 2008). Polyphenols have garnered great interest in research due to their abundance in the 
human diet, as well as antioxidant properties (Manach, et al., 2004). One whole food that is rich 
in polyphenols is the grape (Vitis vinifera). Anthocyanins are the dominant species of polyphenol 
found in red grapes, whereas flavan-3-ols are predominant in white grapes (Perez-Jimenez and 
Saura-Calixto, 2008). In previous research, the effectiveness of grape seed, skin, stem, and extracts 
on CVD risk have all been studied (Perez-Jimenez and Saura-Calixto, 2008). However, the 
consumption of whole grapes as a dietary intervention has not been fully evaluated. (Mozaffarian 
et al., 2015) 
The objective of this study was to examine the effects of GRAPE on adults with MetS. We 
hypothesized that whole grape consumption would positively impact the metabolic profile of male 
and female adults with MetS. For this study, we had two specific aims. Aim 1 attempted to 
determine the effect of whole grape consumption on cardiometabolic risk factors pivotal to MetS 
assessment. It was our hypothesis that ingestion of whole grapes would positively impact the 
cardiometabolic profile of adults with MetS when compared to a placebo. Aim 2 attempted to 
determine the effect of whole grape consumption on inflammation, oxidative stress, and insulin 
resistance in adults with MetS. It was our hypothesis that ingestion of whole grapes will positively 
impact markers of inflammation, oxidative stress, and insulin resistance when compared to a 
placebo. 
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Chapter 1: Review of Literature 
CHRONIC DISEASE 
In the United States, cardiovascular disease (CVD) accounted for 30.8% of all deaths in 
2013 (American Heart Association Statistical Update, 2016). The number one cause of death in 
adults over 65 years of age are diseases of the heart. Approximately 80% of CVDs can be prevented 
through lifestyle modification. These modifications include: not smoking/cessation, engaging in 
routine physical activity, controlling high blood pressure and elevated blood lipid concentrations, 
and maintaining a healthy diet (American Heart Association Statistical Update, 2016). 
Diabetes is another chronic disease of concern. It is a cluster of metabolic diseases that are 
characterized by hyperglycemia (American Diabetes Association, 2014). This is the result of 
defects in insulin secretion, insulin action, or both processes. The chronic hyperglycemia seen in 
type 2 diabetes mellitus (T2DM) can lead to long term damage of: kidneys, nerves, the eyes, and 
heart and blood vessels. Overall, T2DM accounts for ~90-95% of total cases of diabetes in the 
U.S. (American Diabetes Association, 2014). Type 2 diabetes mellitus is a form of diabetes which 
is characterized by insulin resistance, rather than absolute insulin deficiency (Type 1, auto-immune 
disorder). As of 2012, in the United States, an estimated 21.1 million adults had been diagnosed 
with T2DM, with an estimated 8.1 million going undiagnosed (American Heart Association 
Statistical Update, 2016). An even larger number of U.S. adults are estimated to have prediabetes 
(fasting plasma glucose 100-126 mg/dL) at 80.8 million (35.3%). One risk factor that links both 
CVD and T2DM is obesity. Over the last ~30 years, obesity in the United States has increased in 
adults above the age of 20 from 23% (1988-1994) to 34% (2007-2008) (Ogden et al., 2010). 
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OBESITY 
 Obesity is the excess accumulation of body fat. As shown in the previous definitions, 
central obesity is an important risk factor to consider when examining MetS. Obesity is defined by 
WHO and the National Institutes of Health (NIH) as an individual having a BMI >30kg/m2 
(Nguyen et al., 2010). Those with obesity have a low-level of chronic inflammation. This can lead 
to an increase in risk for several chronic diseases including: T2DM, hypertension, CVD, and 
cancer (Nguyen et al., 2010 and National Institutes of Health, National Cancer Institute, 2017). 
Obesity can also be related to a host of digestive disorders, including: gastroesophageal reflux 
disease, colorectal polyps, and liver disease.  
 When cells accumulate more free-fatty acids (FFA) than those required for energetic 
processes, they are esterified and stored as triglyceride (TG) in lipid droplets. Adipocytes have a 
unique capacity to mobilize these fatty acid stores through the action of lipases (Schaffer, 2003). 
Non-adipose cells have a limited capacity for such storage, and when this capacity is exceeded 
dysfunction or cell death may occur; this is termed lipotoxicity.  
LIPOTOXICITY- THE INDUCTION OF DYSFUNCTION 
 In a state of high plasma FFA or TG, the excess may be redirected to non-adipose tissues. 
In the pancreas, FFA dysregulate insulin secretion through many potential mechanisms, including 
effects on peroxisome proliferator-activated receptor alpha (PPARα), glucokinase, and insulin-
dependent glucose transporter 2 (GLUT2) expression (Shaffer, 2003). It has been shown in vitro 
in primary rat pancreatic β-cells, as well as in human β-cell lines that excess FFA can lead to 
cellular apoptosis (Prentki et al., 2002). The extent of caspase activation increases with larger 
glucose concentrations. This suggests that the toxic effects of FFA and glucose are synergistic.  
Page 5 of 47 
In the liver, TG and FFA accumulation is associated with non-alcoholic steatohepatitis 
(NASH). Non-alcoholic steatohepatitis is usually found in obese subjects and can progress to 
cirrhosis (Garg and Misra, 2002). Metabolic abnormalities associated with insulin resistance are 
also seen in high prevalence in those with NASH. Hepatic uptake of FFA is unregulated, and if 
circulating levels of FFA are high, then the liver will take them into its cells. Liver fatty acid 
binding protein (FABP) is present in the cytosol of hepatocytes. In the absence of FABP, 
hepatocytes are seemingly protected against saturated-fat induced TG deposition (Malhi and 
Gores, 2008). In the fatty liver, circulating FFA can activate many intracellular responses such as: 
C-jun N-terninal kinase (JNK) activation, toll-like receptors (TLRs) activation, and endoplasmic 
reticulum (ER) stress.  
JNK is activated by FFA, in accordance with their toxicity. Free-fatty acid activation of 
JNK can lead to improper phosphorylation of insulin receptor substrate 1 (IRS-1), with the 
substitution of serine for tyrosine; resulting in insulin resistance (Shoelson, 2006). FFA also serve 
as ligands for TLRs in times of metabolic dysregulation, this represents an external cellular stress. 
An internal cellular stressor comes in the form of ER stress. Both TLR activation and ER stress 
can activate IKKβ, leading to NF-κB translocation to the nucleus (Shoelson, 2006). The products 
of NF-κB are often shown to induce or promote insulin resistance and include pro-inflammatory 
cytokines. These cytokines include, but are not limited to: TNF-α, interleukin 6 (IL-6), and 
monocyte chemoattractant protein-1 (MCP-1). 
TNF-α was one of the first pro-inflammatory cytokines identified in the systemic response 
to be linked to the development of insulin resistance (Fernandez-Sanchez et al., 2011). The activity 
of TNF-α increases the release of FFA from adipocytes and blocks the synthesis of adiponectin, 
which sensitizes adipose tissue to insulin. It also interferes with the tyrosine phosphorylation of 
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IRS-1. TNF-α also can activate NF-κB signal transduction, leading to the production of cellular 
adhesion molecules, and an inflammatory state in the adipocyte (Fernandez-Sanchez et al., 2011). 
TNF-α can also stimulate the expression of IL-6 and MCP-1 (Kern et al., 2001) These molecules 
attract inflammatory cells to the afflicted area and generate a larger inflammatory response. 
Inflammation is not the sole contributor to insulin resistance. Oxidative stress can result in 
the dysfunction of insulin-related pathways (Keane et al., 2015). Excessive generation of reactive 
oxygen species (ROS) can lead to the damage of DNA, protein, and lipid membranes. Oxidative 
stress via ROS can be the result of over nutrition in the form of high glucose and lipid diets (Keane 
et al., 2015). This over nutrition can lead to the dysfunction of the electron transport chain, which 
produces increased ROS. Another pathway that ROS may be generated is via superoxide 
dismutase. Superoxide can be converted to H2O2, which is much more stable. However, H2O2 itself 
can react with Fe2+ to produce a highly reactive hydroxyl radical (OH•) (Keane et al., 2015). The 
consequences of all this damage is ultimately cell death and an inflammatory response. However, 
the body has endogenous antioxidant systems to help off-set H2O2 build-up. Glutathione 
peroxidase and catalase are endogenous peroxidases that facilitate the decomposition of H2O2 to 
H2O.  
METABOLIC SYNDROME CLASSIFICATION 
Metabolic Syndrome is considered to be a constellation of symptoms that increases the risk 
for T2DM and CVD (Fernandez, 2007). The rate of MetS in the United States is ~34% (American 
Heart Association 2016). The criteria and cut-offs for the classification of MetS vary between 
health agencies. Some common health agency definitions are listed below in Table 1.4.1. The 
most common criteria used for MetS classification are: reduced high-density lipoprotein 
cholesterol (HDL-C) concentrations, as well as increased plasma triglyceride (TG), blood glucose, 
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blood pressure (BP), and waist circumference (WC). The World Health Organization (WHO) 
definition of MetS assumes that insulin resistance is one of the major underlying contributors to 
the condition (World Health Organization, 1999). Thus, there is no fasting plasma glucose 
requirement; it requires instead a surrogate for insulin resistance such as glucose intolerance, 
impaired glucose tolerance (IGT), insulin resistance, or diabetes. This definition is somewhat 
controversial. To include insulin resistance makes it difficult to determine the lowest quartile of 
insulin sensitivity, which must be done using a clamp procedure, and is not feasible in clinics and 
epidemiological studies (Alberti et al, 2006). This definition also includes waist-to-hip ratio 
(WHR) as a measure of central obesity, which is relevant as a simple estimator of disease outcome. 
However, waist circumference is a more relevant index of central obesity, which correlates with 
negative metabolic variables (Janssen et al., 2004).  
The European Group for the Study of Insulin Resistance (EGIR) proposed a modified 
model after WHO released its version in 1999 (Balkau et al., 1999). This modified method 
discontinued the physical measure of insulin using a euglycemic clamp. Instead, the EGIR 
proposed using a fasting plasma insulin level to estimate insulin resistance. To qualify, individuals 
would have to be within the top 25% of fasting plasma insulin values in a non-diabetic population. 
Additionally, the EGIR called for impaired fasting glucose (IFG) to replace IGT. This new 
definition also slightly altered the cut-off values for TG and HDL-C as well as being defined on 
treatment for dyslipidemia or hypertension as inclusion criteria. 
The National Cholesterol Education Program- Third Adult Treatment Panel (NCEP-ATP 
III) proposed its definition of MetS in 2001 as a prevention method for coronary heart disease 
(CHD). Unlike previous methods of diagnosis, it does not include an insulin resistance component. 
The NCEP-ATP III definition does not require a glucose component like the previous definitions. 
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Instead, each risk factor is weighted evenly and an individual must have three of the five to have 
MetS. This definition also includes waist circumference as its measure of central obesity, similar 
to EGIR. 
The American Association of Clinical Endocrinology (AACE) released its position on 
insulin resistance syndrome in 2002. The AACE statement does not include a specified number of 
risk factors to qualify, and allows for clinical judgement when identifying MetS in individuals 
(Einhorn, 2003). However, when diagnosed with diabetes, the individual is no longer considered 
to have insulin resistance syndrome. 
Taking these definitions into account, the International Diabetes Federation (IDF) also 
released its own stance on MetS. This is considered to be a world-wide definition to be used in 
epidemiological and clinical practice (Alberti, et al., 2006). This definition was produced out of 
clinical practicality. The IDF used the NCEP-ATP III as a starting point because this definition 
did not include measurements of insulin resistance, which requires a very involved process. Insulin 
resistance is a key component of MetS, however the IDF definition focuses on WC. This is because 
it is an easy measure for clinical purposes and provides an accurate assessment of central obesity 
(Janssen et al., 2004). 
DIETARY INTERVENTION 
Increasing evidence suggests that eating a diet rich in fruit and vegetables plays a key role 
in the prevention of chronic diseases, such as T2DM, CVD, and certain cancers (Liu, 2013). 
Bioactive components of these plant-based foods are theorized to explain the association between 
fruits and vegetables and decreased risk for chronic disease. Phytochemicals are an example of a 
class of bioactive molecules exclusive to plant-based foods (Liu, 2013). Polyphenols are a complex 
and diverse group of phytochemicals with numerous subclasses, present in many plant-based 
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foods. It has been shown that many fruits contain high amounts of polyphenols; wild blueberry 
(429 ± 10 mg of GAE /100 g), blackberry (412 ± 6 mg of GAE/100 g), cranberry (287 ± 5 mg of 
GAE/100 g), and red grape (161 ± 7 mg of GAE/100g) were among the top ten fruits of 25 analyzed 
in one particular study (Wolfe et al., 2008). Grapes are an important contributor of polyphenols to 
the American diet (12.8% of total phenolics). Grapes also show high antioxidant capacity in cell 
studies, ranking 4th among 25 common fruits analyzed (Wolfe et al., 2008). Thus, whole grapes 
and grape products could be used as a dietary intervention when attempting to combat a chronic 
disease such as MetS.  
 For the benefit of research, the California Table Grape Commission has developed a 
standardized, freeze-dried, whole grape powder (GRAPE). Within this powder are seeded and 
seedless, red, green, and black table grapes in proportion with the annual crops (van Breeman et 
al., 2016). Chemical analysis is carried out on the powder to quantify the polyphenols within the 
powder. These polyphenols include: catechin, epicatechin, flavanols (quercetin, kaempferol, 
isorhamnetin), anthocyanidins (malvidin, peonidin, cyanidin), and resveratrol. Separate powders 
have been developed for human clinical trials and animal trials. For human clinical trials, a placebo 
powder has been developed that matches the GRAPE in kcals, color, texture, and flavor. In animal 
studies only a sugar-matched powder is used as a control. Long-term, easily reproducible, studies 
on the health benefits of whole grapes may be carried out with an appropriately matched placebo 
powder as a result of this development. 
USE OF GRAPE AS INTERVENTION IN HUMANS 
 The standardized, freeze-dried, grape powder has been used in trials relating to 
cardiometabolic health in humans. Zern et al., (2005) conducted a study in women (24 pre-
menopausal, 20 post-menopausal) to evaluate the effectiveness of GRAPE on plasma lipids, 
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inflammatory cytokines, and oxidative stress. The study design was randomized, single-blind, 
placebo-controlled, crossover. Subjects were instructed to consume 36g/day of GRAPE or placebo 
powder for four weeks, then entered a three-week washout. After the washout, subjects began the 
second arm, for four more weeks of the study on the opposite powder. Intake of GRAPE 
significantly decreased TG concentrations in both pre- and post-menopausal women by 15 and 
6%, respectively (p < 0.002) compared to placebo. Menopausal status had no effect on plasma 
cytokine concentrations. However, ingestion of GRAPE significantly decreased TNF-α in both 
pre- and post-menopausal groups (p < 0.05). 
 Barona et al., (2012) conducted a study in men evaluate the effectiveness of GRAPE on 
MetS. Twenty-four men, aged 30-70 years were randomly assigned to this double-blind, placebo-
controlled, crossover study. Subjects were instructed to consume 46g/day of GRAPE or placebo 
powder for thirty days, then entered a three-week washout. After the washout, subjects began the 
second arm of the study for thirty more days, on the opposite powder. Intake of GRAPE 
significantly reduced systolic blood pressure compared to placebo (122 ± 11 mmHg vs. 128 ± 10 
mmHg, (p < 0.025). Plasma soluble vascular cell adhesion molecule-1 (sICAM-1) was lowered in 
the GRAPE group (142 ± 50 µg/L) compared to placebo (151 ± 51 µg/L) (p < 0.025). The decrease 
in sICAM-1 suggests function is being restored to the endothelium. 
Upon further analysis of the same cohort, Barona et al., (2012) examined the effectiveness 
of GRAPE on MetS in the presence or absence of dyslipidemia. At baseline, these subjects were 
classified as dyslipidemic (HDL-C ≤40mg/dL and TG ≥150mg/dL) and non-dyslipidemic. All 
subjects significantly decreased their systolic blood pressure after ingestion of GRAPE compared 
to placebo (p <0.0025). In the dyslipidemic group adiponectin (p <0.05) and interleukin 10 (IL-
10) (p <0.005) were decreased. The non-dyslipidemic group the opposite, with an increase in 
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adiponectin (p <0.05) and IL-10 (p <0.005). The GRAPE increased IL-10 and adiponectin, two 
anti-inflammatory proteins, in the non-dyslipidemic group. It was the conclusion of this author 
that people with dyslipidemic MetS have a lower number of anti-inflammatory HDL and more 
pro-inflammatory small dense LDL; this may provide a more inflammatory environment; thus, 
cells may be less responsive than their non-dyslipidemic counterparts. 
Zunino et al. conducted a study to evaluate the effectiveness of GRAPE on obese 
individuals. Twenty-four obese adults (BMI 30-45kg/m2), aged 20-60 years, were randomly 
assigned to this double-blind, placebo-controlled, crossover study. Subjects were instructed to 
consume 46g/day of GRAPE or placebo powder for three weeks, then entered a three-week 
washout. After the washout, subjects began the second arm of the study for three more weeks, on 
the opposite powder. Intake of GRAPE significantly reduced systolic blood pressure compared to 
placebo (117.5mmHg vs. 122.6mmHg, p < 0.049) over the first two weeks of the intervention. At 
week three, change was no longer significant. Using nuclear magnetic resonance spectroscopy 
(NMR), lipoproteins can be quantified into subclasses (Jeyarajah et al., 2006). It was observed that 
GRAPE significantly reduced NMR-large LDL and NMR-LDL-C concentrations in plasma after 
the three-week intervention (p < 0.05). Additionally, GRAPE significant reduced VLDL size 
compared to placebo after two weeks (52.9nm vs. 56.9nm, p = 0.041). This significance was not 
apparent after final week of the three-week intervention. This group also showed that interleukin 
1β (IL-1β) (p = 0.041) and IL-6 (p = 0.018) increased significantly in LPS-stimulated peripheral 
blood mononuclear cells (PBMCs) in the GRAPE group. The combination of IL-1β and IL-6 will 
work in concert to stimulate phagocytosis of pathogens. This data suggests that GRAPE may 
sensitize the immune cells in obese individuals. 
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CONCLUSIONS 
 The American heart association has stated the rate of MetS in the United States is ~34% 
(American Heart Association 2016). Metabolic syndrome can result in a multitude of 
complications because of the wide range of inclusion. Central obesity is a major contributing factor 
to the development of lipotoxicity. Lipotoxicity can result in the production of pro-inflammatory 
cytokines, ER stress, and insulin resistance. These are just three underlying factors that can 
contribute to the advancement of MetS. As a dietary intervention, grapes and grape products have 
shown promising results in cell, animal, and human research to provide relief of these 
comorbidities. The California Table Grape Commission has developed a standardized, freeze-
dried, grape powder for use in clinical and animal trials. This allows for more reliable, 
reproducible, studies to be conducted on long-tern whole grape ingestion. However, more research 
is needed in areas related to humans with whole grape consumption. The GRAPE has been used 
in some clinical trials with male and female subjects, and even in those with MetS. These studies 
have shown promising results. However, few studies exist to date that examine the effects of whole 
grape consumption on MetS and its underlying drivers, inflammation, oxidative stress, and insulin 
resistance.  
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WHO EGIR  NCEP ATP III AACE IDF 
 
Glucose intolerance, IGT, diabetes, and/ or 
IR with 2 of the following: 
Insulin resistance plus 2 of 
the following: 
Three of the 
following: 
No defined number of 
risk factors 
Elevated WC (ethnicity 
specific) plus 2 of the 
following: 
Fasting Plasma 
Glucose 
 >110 mg/dL, non-diabetic >100 mg/dL >110-126 mg/dL >100 mg/dL or T2DM 
Blood Pressure ≥140/90 mmHg ≥140/90 mmHg or treatment ≥130/≥85 mmHg ≥130/≥85 mmHg ≥130/≥85 mmHg 
Triglycerides ≥150 mg/dL >178 mg/dL or treatment ≥150 mg/dL ≥150 mg/dL ≥150 mg/dL 
HDL Cholesterol 
Men: 
Women: 
 
<35 mg/dL 
<39 mg/dL 
<39 mg/dL or treatment 
 
<40 mg/dL 
<50 mg/dL 
 
<40 mg/dL 
<50 mg/dL 
 
<40 mg/dL 
<50 mg/dL 
Central Obesity 
Men: 
Women: 
Waist: hip 
>0.90 
>0.85 
BMI (and/or) 
>30 kg/m² 
Waist circumference 
≥94 cm 
≥80 cm 
Waist 
circumference 
≥102 cm 
≥88 cm 
BMI ≥25 kg/m² 
Europids 
Male ≥94 cm 
Female≥80 cm 
South Asians 
Male ≥94 cm 
Female≥80 cm 
Chinese 
Male ≥94 cm 
Female≥80 cm 
Japanese 
Male ≥94 cm 
Female≥80 cm 
 
Other ethnicities not 
defined due to lack of 
data. Use Europid data. 
Other 
Urinary albumin 
excretion rate: 
≥20 ug 
Albumin: Creatinine 
≥30 mg/g 
  
2-hour Post glucose 
challenge >140 mg/dL 
Table 1.4.1.  Differences in agencies when establishing a definition for MetS. Adapted from Alberti et al. (2006) 
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Chapter 2: Effects of GRAPE on 
Cardiometabolic Risk Factors in Adults with 
Metabolic Syndrome 
Introduction 
Some of the identified risk factors for CVD overlap with those of T2DM. Some of these 
risk factors include: obesity, dyslipidemia, and hypertension. In the United States, 69% of adults 
are overweight and 35% are obese. The burden of cost per capita for obesity in the United States 
is $1160 for men and $1525 for women (American Heart Association, 2016). Approximately 25% 
of U.S. have high TG (>150 mg/dL). Roughly 80 million U.S. adults have hypertension, which 
equates to 32.6%. The very high rates of risk factors for T2DM and CVD has led to the recognition 
of metabolic syndrome MetS (National Institutes of Health, National Heart, Lung, and Blood 
Institute, 2016).  Metabolic syndrome is a constellation of symptoms that together, increases the 
risk for development of T2DM and CVD. 
 The symptoms of MetS include: decreased concentrations of high-density lipoprotein 
cholesterol (HDL-C), and elevated plasma triglycerides (TG), fasting blood glucose, systolic blood 
pressure (SBP) or diastolic blood pressure (DBP), and elevated waist circumference (WC). Having 
three of the five previously mentioned symptoms qualifies an individual as having MetS (National 
Institutes of Health, National Heart, Lung, and Blood Institute, 2016).  
The management of these factors is treated similar to those in the chronic disease state. 
However, when disease in in full-blown progression dietary intervention is often forgone. 
Metabolic syndrome is simply a cluster of risk factors that increases one’s risk for disease. 
According to Grundy et al., (2005), addressing physical inactivity and nutritional status are first 
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line defenses in MetS. It is recommended to avoid a more atherogenic profile, a diet roughly 30% 
fat is taken by the individual, in order to reduce the risk of decreasing HDL further. It is also 
recommended to intake a high amount of fruits and vegetables.  
Data has shown that increased consumption of fruit and vegetables is correlated with 
reduced risk for all-cause mortality and CVD (Wang et al., 2014). This is theorized to be due to 
the bioactive components of these foods, such as vitamin C, vitamin E, carotenoids, and 
polyphenols (Perez-Jimenez and Saura-Calixto, 2008). Polyphenols have garnered great interest 
in research due to their abundance in the human diet, as well as antioxidant properties (Manach, et 
al., 2004). One whole food that is rich in polyphenols is the grape (Vitis vinifera). In previous 
research, the effectiveness of grape seed, skin, stem, and extracts on CVD risk have all been studied 
(Perez-Jimenez and Saura-Calixto, 2008). However, the consumption of whole grapes as a dietary 
intervention has not been fully evaluated (Mozaffarian et al., 2015). It is our hypothesis that 
ingestion of whole grapes will positively impact the cardiometabolic profile of adults with MetS 
when compared to a placebo.  
Materials and Methods 
OVERVIEW OF STANDARDIZED GRAPE POWDER AND PLACEBO POWDER 
Standardized Grape Powder 
Standardized grape powder (GRAPE) is used within clinical research and animal studies. 
The GRAPE is made from a combination of green, red, and black grapes of the seeded and seedless 
variety. The proportion of green, red, and black grapes in the GRAPE is in accordance with annual 
production, as noted by the California Table Grape Commission (van Breemen, R. B et al., 2016; 
California Table Grape Commission, 2016). These grapes are frozen and ground with food grade 
dry ice and reground to ensure a fine consistency (National Foods Lab; Livermore, CA). The 
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GRAPE also contains silicon dioxide as an anti-caking agent (van Breemen, R. B et al., 2016; 
California Table Grape Commission, 2016). A standard serving of fresh grapes is ~126 g. It has 
been calculated previously that 100 g of fresh grapes is equal to 18.2 g of GRAPE. Since one 
serving of fresh grapes is ~126 g, one serving of grapes is equal to 23 g of GRAPE. (California 
Table Grape Commission, 2016) Nutrient composition of GRAPE according to the California 
Table Grape Commission can be found in Table 2.2.1. 
Placebo Powder 
The placebo powder, for use in human clinical trials, is produced to mimic the 
characteristics of the GRAPE. Also produced by the California Table Grape Commission, the 
placebo is matched to the GRAPE in certain characteristics including: dietary fiber, sugar profile, 
organic acid profile, and other sensory characteristics. Fresh grapes contain 0.2-0.8% organic 
acids, including tartaric, malic, and citric acids, these were added in proportion to the placebo 
powder. Silicon dioxide was also added in the same quantity as the GRAPE for anti-caking (van 
Breemen, R. B et al., 2016; California Table Grape Commission, 2016).  
Table 2.2.1. Summary of Nutrients in the Grape Powder 
Nutrient Amount (per 100g) 
Calories 371 kcal 
Total Fat 0.299 g 
Total Carbohydrate 88.6 g 
Protein 3.58 g 
Beta-Carotene 0.127 mg 
Vitamin A 212 IU 
Vitamin C 2.7 mg 
Calcium 50 mg 
Iron 1.43 mg 
Sodium 11.8 mg 
Potassium 973 mg 
Thiamine HCl 0.17 mg 
Folic Acid 49 mcg 
Phosphorus 104 mg 
Magnesium 33.3 mg 
Zinc 0.416 mg 
Copper 0.450 mg 
Manganese 0.379 mg 
Moisture 4.52 g 
Ash 3.02 g 
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Table 2.2.2. Summary of Phytochemical Composition of Grape Powder 
Compounds Total (mg/kg) Individual (mg/kg) 
Catechins  135.4  
Catechin  77.4 
Epicatechin  58.9 
Anthocyanins 533.65  
Peonidin  47.63 
Cyanidin  266.7 
Malvidin  219.32 
Flavonols   
Quercetin  148.7 
Kaempferol  7.38 
Isorhamnetin  13.95 
Stilbenes   
Resveratrol  13.6 
Total Polyphenols 
(Gallic Acid Equivalents) 
3260  
 
HUMAN SUBJECTS AND INTERVENTION 
Recruitment 
Adults aged 30-70 were recruited using flyers, email, and in-person methods. Flyers were 
posted throughout the University of Connecticut campus (Storrs, Connecticut) and surrounding 
area in approved locations. Local and university events were also used to recruit subjects. Study 
overview sheets and flyers were brought to local and university events in order to assist study staff 
in recruitment.  
Enrollment Totals 
The total number of individuals prescreened for the study was 53. Of those 53 individuals, 43 
continued with an in-person screening. Twenty-nine individuals qualified for the study after the 
screening process, six chose not to participate. Of the remaining 23 participants, three dropped 
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while on study. Twenty participants completed the study (n = 20). Of the 20 subjects finished, 12 
subjects were male and 8 were female. 
Pre-screening 
Potential subjects were emailed or called on the telephone to follow-up and gauge interest 
and eligibility. Pre-screening questions addressed broad inclusion and exclusion criteria, as well 
as their ability to comply with the study and its time commitments. After these questions, if the 
individual was still interested in the study, and appeared to be eligible, a screening visit would be 
scheduled. 
Screening 
Once recruited, individuals were screened. During the screening visit the experimental 
procedure and time commitments of the study were explained. Consent was obtained before any 
personal information was collected.  Inclusion criteria for the study was based on a modified 
version of the NCEP ATP-III criteria for metabolic syndrome. Potential subjects had to meet these 
criteria, or be taking blood pressure medication as an alternative for the hypertension criteria. 
Exclusion criteria included: not having metabolic syndrome, having a history of major chronic 
disease (e.g. cancer, diabetes, CVD), weight fluctuation greater than ± 10% over the previous four 
weeks, taking lipid or glucose altering medication, taking anti-inflammatory medication, 
exceeding “extreme risk” for any of the inclusion criteria [TG (>500 mg/dL), TC (>300 mg/dL), 
blood glucose (>126 mg/dL), WC (>200cm), or BP (>160/100 mmHg)] ), or allergy to the powder 
or its ingredients. After obtaining consent, the individual filled out a medical history form for the 
study staff to keep on file. Once paperwork was completed, anthropometric data was collected. 
Blood pressure and pulse were measured using an electronic sphygmomanometer (Omron, 
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Healthcare Inc., Bannockburn, IL). Body weight was measured and recorded in kilograms. Height 
was measured and recorded in inches then converted to meters. Waist circumference was measured 
using a non-flexible waist measuring tape above the iliac crest and recorded in centimeters. After 
recording the anthropometric measures, a finger prick was conducted and blood was collected via 
capillary tube. Individuals were fasted for twelve hours previous to the blood collection to assure 
accurate values. Blood samples were immediately analyzed using an Alere Cholestech LDX 
Analyzer (MedTeck, Salt Lake City, UT). Individuals were notified immediately of qualification 
or disqualification. If their values did not fit within the specified inclusion criteria, they were 
informed they did not qualify. However, if any of their values were within the “extreme risk” 
range, they were not enrolled and advised to see a doctor. If the individual being screened met the 
study inclusion criteria and was willing to continue with enrollment they were given required study 
materials and scheduled a start date.  
Table 2.2.3. Summary of NCEP/ATP-III Criteria for MetS. 
NCEP ATP III 
Three of the following: 
Fasting Plasma Glucose >100 mg/dL 
Blood Pressure 
 
Systolic 
Diastolic 
 
 
≥130 mmHg 
≥85 mmHg 
Triglycerides ≥150 mg/dL 
HDL Cholesterol 
 
Men: 
Women: 
 
 
<40 mg/dL 
<50 mg/dL 
Waist circumference 
 
Men: 
Women: 
 
 
≥102 cm 
≥88 cm 
 
Intervention 
The intervention was a randomized double-blind, placebo-controlled, crossover study. 
Neither the subjects, nor the investigators, were aware of the identity of the placebo or GRAPE 
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throughout the duration of the intervention. Subjects were assigned a number according to their 
entry into the study. Once qualified for the study, subjects were randomly assigned to an 
intervention powder. Subjects were instructed to ingest one 30 g packet of powder approximately 
30 minutes after the morning meal and another packet of powder approximately 30 minutes after 
the evening meal. Total powder ingestion was 60 g/day (prepackaged powder prepared by the 
California Table Grape Commission, Fresno, CA). Sixty grams/day of grapes is roughly 2.5 cups, 
and provides ~200 mg polyphenols. Upon starting the study, subjects entered a run-in phase. The 
run-in phase consisted of two weeks of avoiding restricted foods that were provided in a list to the 
subject. These restricted foods were to be avoided throughout the duration of the intervention. 
During the second week of the run-in phase, subjects recorded their diet and exercise habits. After 
the run-in phase, subjects began their first intervention powder for the first four weeks of the 
intervention. For this arm, subjects were instructed to continue avoiding the restricted foods. After 
the first arm of the intervention, subjects entered a three-week washout, to normalize any potential 
metabolic changes. The second arm of the study mirrored the first, the exception being subjects 
consumed the opposite intervention powder.  
BLOOD PROCESSING AND STORAGE 
Twelve- hour fasting blood samples were collected at baseline and after four weeks for 
both arms of the study. During the two baseline visits, four tubes of blood were collected to use 
for plasma and two were collected for serum. During the two end-point visits, two tubes were 
collected for plasma and serum, respectively. Blood samples were collected using BD Vacutainer 
serum-separator, and EDTA plasma tubes (Becton, Dickinson, and Company, Franklin Lakes, NJ). 
Blood samples were centrifuged at 2400 RPM for 11 minutes at 4°C. Once finished centrifuging, 
plasma was collected from EDTA tubes and aliquoted into a separate 15mL tube. Bovine aprotinin 
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from a stock of 7500-13,000 U/mL was added to the plasma to inhibit serine proteases. A final 
concentration of ~1000 U/L was desired, thus 1 µL of stock was added per 1 mL of plasma. Phenyl 
methyl sulfonyl fluoride (PMSF) from a stock of 100 mM was also added to inhibit serine and 
cysteine proteases. A final concentration 100 nM was desired, thus 1 µL of PMSF was added per 
1 mL of plasma. The final ratio of plasma to protease inhibitors was 1mL plasma: 1 μL aprotinin: 
1 μL PMSF. The contents of this tube were transferred to 1.5mL Eppendorf tubes (Eppendorf 
North America, Hauppauge, NY) in 500 μL aliquots and stored at -80°C for later analysis. Once 
finished centrifuging, serum from serum-separator tubes was transferred neat into 1.5 mL 
Eppendorf tubes in 500 μL aliquots and stored at -80°C for later analysis. 
DIETARY ANALYSIS, EXERCISE RECORDS, AND COMPLIANCE 
Upon enrollment in the study, subjects were provided with a series of dietary and exercise 
records. Subjects were provided with a 5-day diet record, and a 7-day exercise record. The purpose 
of these records was to review and ensure compliance as well as consistency in the diet and 
exercise patterns. Subjects were to fill out the 5-day and 1-day diet records in the six days prior to 
the baseline blood draws for each arm of the study. Subjects were only required to fill out the 5-
day diet record for the end-point blood draws. Subjects had were to fill out the exercise records 
the week prior to each blood draw. Using NDSR dietary analysis software, (University of 
Minnesota, Minneapolis, MN) subject diet records were analyzed for significant changes. 
Compliance to the study powders was measured in several ways. First, subjects were given 
hard copy records to fill out daily and weekly. Included within these records were questions about 
adhereance and compliance in additon to the the foods to be avoided inn the restricted list. Next, 
study participants were asked to bring empty packets to their end-point visits. Study staff then 
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counted these packets to ensure the number of empty packets matched up with the hard copy 
records. 
SERUM BIOCHEMICAL ANALYSIS 
 Plasma Lipids, Glucose, ALT    
Total cholesterol, HDL-C, TG, glucose, and alanine amino transferase (ALT), were 
measured using enzymatic and photometric assays via a COBAS c111 Analyzer (Roche 
Diagnostics International Limited, Rotkreuz, Switzerland). Non-HDL-C was calculated by 
subtracting HDL-C from TC. LDL-C was calculated using the Friedewald method. Samples from 
baseline and end-point for each arm were run simultaneously to minimize variance. 
STATISTICAL ANALYSIS 
Differences between end-points of groups were evaluated by independent t tests 
(significance = p < 0.05). Two-way repeated measures ANOVA was used to determine the effect 
of the intervention for variables with baseline measures, with the within subject variables as 
treatment (tests GRAPE vs. placebo effect) and between subjects-variable as sequence order (tests 
carryover effect). All statistical analysis was done using IBM SPSS Statistics software. Data are 
reported as mean ± SEM.  
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Results 
DIETARY INTAKE DURING INTERVENTION 
During the intervention, subjects were instructed not to change their habitual dietary 
patterns. To ensure this, a dietary analysis was performed using NDSR software. Subjects did not 
alter their diets from one arm of the study to another in any of the observed categories. 
Table 2.3.1. Summary of Dietary Intake of Subjects. n = 15. *p < 0.05. 
Variable End-Point 
 
GRAPE vs. Placebo P-value 
Total Energy, kcal  
  
GRAPE 1803.73 ± 249.30 133.93 ± 168.61 0.440 
PLACEBO 1669.80 ± 156.55 
Glycemic Load 
   
GRAPE 102 ± 26.84 14.93 ± 18.28 0.428 
PLACEBO 88.00 ± 10.87 
Total Fat, g     
GRAPE 78.49 ± 9.39 1.42 ± 8.86 
  
0.875 
PLACEBO 77.08 ± 8.74 
Total Carbohydrate, g 
   
GRAPE 191.10 ± 43.75 24.51 ± 25.98 0.361 
PLACEBO 166.59 ± 21.65 
Total Protein, g 
   
GRAPE 83.66 ± 5.49 9.68 ± 5.65 0.109 
PLACEBO 
 
 
73.98 ± 4.13 
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Variable End-Point 
 
GRAPE vs. Placebo P-value 
Total Alcohol, g 
   
GRAPE 3.87 ± 1.78 -1.32 ± 1.31 0.332 
PLACEBO 5.19 ± 2.39 
Cholesterol, mg 
   
GRAPE 335.67 ± 35.18 -3.13 ± 36.36 0.933 
PLACEBO 338.80 ± 41.10 
SFA, g 
   
GRAPE 26.01 ± 3.29 1.81 ± 3.38 0.602 
PLACEBO 24.20 ± 2.76 
 
 
PUFA, g    
GRAPE 17.48 ± 3.07 -0.76 ± 3.05 0.807 
PLACEBO 18.24 ± 2.69 
TRANS, g 
   
GRAPE 2.21 ± 0.36 0.21 ± 0.30 0.496 
PLACEBO 2.00 ± 0.29 
OMEGA 3, g 
   
GRAPE 2.03 ± 0.29 0.09 ± 0.38 0.807 
PLACEBO 1.93 ± 0.28 
Total Dietary Fiber, g 
   
GRAPE 17.84 ± 2.59 1.24 ± 1.42 0.397 
PLACEBO 16.60 ± 2.09 
Vitamin E, IU 
   
GRAPE 16.53 ± 3.16 2.13 ± 2.25 0.358 
PLACEBO 
 
14.40 ± 2.12 
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Variable End-Point 
 
GRAPE vs. Placebo P-value 
Vitamin C, mcg 
   
GRAPE 70.75 ± 9.05 5.02 ± 12.33 0.690 
PLACEBO 65.72 ± 12.30 
Selenium, mcg 
   
GRAPE 110.59 ± 7.47 5.12 ± 6.66 0.455 
PLACEBO 105.47 ± 6.90 
β-Carotene, mcg 
   
GRAPE 3305.13 ± 775.94 -1765.47 ± 1415.45 0.233 
PLACEBO 5070.60 ± 1580.30 
α-Carotene, mcg 
   
GRAPE 473.07 ± 156.09 -972.93 ± 556.76 0.102 
PLACEBO 1446.00 ± 698.59 
Lutein & Zeaxanthin, mcg 
   
GRAPE 3930.67 ± 1414.78 1102.87 ± 1542.33 0.486 
PLACEBO 2827.80 ± 570.36 
Lycopene, mg 
   
GRAPE 7441.20 ± 1639.42 1840.20 ± 1781.44 0.319 
PLACEBO 5601.00 ± 589.01 
Daidzein, mg 
   
GRAPE 0.20 ± .05 -0.04 ± 0.05 0.489 
PLACEBO 0.23 ± 0.07 
Genistein, mg 
   
GRAPE 0.21 ± 0.07 -0.06 ± 0.09 
 
0.463 
PLACEBO 0.28 ± 0.11 
Abbreviations: Saturated fatty acid (SFA), Polyunsaturated fatty acid (PUFA), Trans-fatty acid 
(TRANS), Omega-3 fatty acid (OMEGA 3) 
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EFFECTS OF GRAPE ON ANTHROPOMETRIC VARIABLES 
 When analyzed using two-way ANOVA, it was observed that body weight in the GRAPE 
group was trending toward a minor decrease compared to placebo (0.03 ± 0.33 kg vs. 0.65 ± 0.21 
kg, p = 0.081). Consequently, BMI was observed to be slightly, but significantly (0.01 ± 0.11 
kg/m2 vs. 0.23 ± 0.07 kg/m2, p = 0.048), decreased in the GRAPE group over the 4-week 
intervention period. When stratifying groups into male and female it was seen that GRAPE did 
have a significant effect on anthropometrics. In men, pulse was significantly reduced (-0.64 ± 1.22 
bpm vs. 3.30 ± 1.15 bpm, p = 0.003). 
Table 2.3.2. Summary of Anthropometrics. n=19, male n=11, female n=8 
Variable Baseline Week 4 Change P-value 
Body weight, kg   
  
GRAPE 93.82 ± 3.92 93.85 ± 3.97 0.03 ± 0.33 0.081* 
Male 103.71 ± 4.38 103.86 ± 4.51 0.15 ± 0.55 0.213# 
Female 79.79 ± 4.36 79.70 ± 4.29 -0.09 ± 0.38 0.227$ 
PLACEBO 92.93 ± 3.72 93.55 ± 4.00 0.65 ± 0.21  
Male 102.58 ± 4.12 103.26 ± 4.51 0.68 ± 0.35  
Female 79.59 ± 4.11 80.19 ± 4.09 0.60 ± 0.21  
BMI, kg/m2     
GRAPE 32.93 ± 1.08 32.94 ± 1.07 0.01 ± 0.11 0.048* 
Male 33.58 ± 1.70 33.62 ± 1.71 0.04 ± 0.17 0.184# 
Female 32.06 ± 1.40 32.03 ± 1.35 -0.03 ± 0.16 0.238$ 
PLACEBO 
32.64 ± 1.01 32.92 ± 1.08 0.23 ± 0.07  
Male 33.20 ± 1.60 33.42 ± 1.65 0.22 ± 0.11  
Female 31.99 ± 1.33 32.24 ± 1.32 0.25 ± 0.09  
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Variable Baseline Week 4 Change P-value 
Waist Circumference, cm     
GRAPE 109.07 ± 2.94 108.42 ± 3.10 -0.65 ± 0.52 0.382* 
Male 112.58 ± 4.10 112.69 ± 4.27 0.11 ± 0.41 0.990# 
Female 103.21 ± 4.15 101.52 ± 4.23 -1.70 ± 1.14 0.315$ 
PLACEBO 
107.78 ± 2.72 107.58 ± 2.99 0.02 ± 0.49  
Male 111.18 ± 3.72 111.31 ± 4.06 0.12 ± 0.60  
Female 102.57 ± 4.08 102.45 ± 3.97 -0.62 ± 0.99  
Systolic Blood Pressure, mmHg     
GRAPE 129.04 ± 2.58 129.41 ± 3.10 0.37 ± 2.10 0.516* 
Male 132.21 ± 3.92 133.82 ± 4.52 1.61 ± .19 0.672# 
Female 124.49 ± 3.17 122.07 ± 3.41 -2.42 ± 4.23 0.414$ 
PLACEBO 131.27 ± 2.98 133.02 ± 3.84 1.74 ± 2.24  
Male 136.06 ± 4.08 136.85 ± 6.04 0.79 ± 3.47  
Female 124.71 ± 4.10 127.75 ± 3.38 3.03 ± 2.58  
Diastolic Blood Pressure, mmHg      
GRAPE 85.16 ± 1.64 86.37 ± 1.88 1.21 ± 1.23 0.485* 
Male 86.94 ± 2.28 88.64 ± 2.46 1.70 ± 1.43 0.216# 
Female 83.24 ± 2.58 82.75 ± 3.01 -0.49 ± 2.14 0.700$ 
PLACEBO 87.32 ± 1.75 87.05 ± 1.90 -0.49 ± 1.25  
Male 89.70 ± 1.98 88.70 ± 2.64 -1.00 ± 1.56  
Female 84.58 ± 3.24 84.79 ± 2.67 0.21 ± 2.17  
Pulse, beats/min     
GRAPE 67.34 ± 2.39 66.93 ± 2.53 -0.42 ± 1.39 0.533* 
Male 68.00 ± 3.63 67.36 ± 4.43 -0.64 ± 1.22 0.003# 
Female 65.78 ± 3.44 67.29 ± 1.93 1.50 ± 2.59 0.444$ 
PLACEBO 66.35 ± 2.36 67.70 ± 2.25 1.17 ±1.09  
Male 64.27 ± 3.40 67.57 ± 3.54 3.30 ± 1.15  
Female 69.63 ± 3.53 67.87 ± 2.52 -1.76 ± 1.60  
* = comparison of GRAPE vs. placebo in entire population, # = comparison of GRAPE vs. placebo in 
male subset, $ = comparison of GRAPE vs. placebo in female subset.  
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EFFECTS OF GRAPE ON PLASMA VARIABLES 
   Using a two-way ANOVA, plasma lipids, fasting glucose, and plasma ALT were 
compared over the 4-week period. None of the plasma variables measured significantly changed 
after four weeks in the GRAPE or placebo groups. However, when stratified for sex, male subjects 
in the GRAPE group had a significant decrease in TG (-35.00 ± 15.79 mg/dL vs. 8.45 ± 11.57 
mg/dL, p = 0.033). Female subjects had a significant increase in TC (-0.75 ± 6.55 mg/dL vs -6.00 
± 5.94 mg/dL, p = 0.003), Non-HDL-C (3.75 ± 5.55 mg/dL vs. -3.75 ± 3.97 mg/dL, p = 0.010), 
and LDL-C (1.43 ± 5.21 mg/dL vs. -6.30 ± 4.67 mg/dL, p = 0.049) with GRAPE ingestion 
compared to placebo.  
Table 2.3.3. Summary of plasma lipids, glucose, and ALT. n=19, male n=11, female n=8. 
Variable Baseline Week 4 Change P-value 
Total Cholesterol, mg/dL  
  
GRAPE 197.21 ± 10.72 190.47 ± 10.98 -6.74 ± 4.77 0.374* 
Male 187.73 ± 16.43 176.64 ± -11.09 -11.09 ± 6.66 0.206# 
Female 210.25 ± 11.36 209.50 ± 15.87 -0.75 ± 6.55  0.003$ 
PLACEBO 196.89 ± 9.14 196.95 ± 11.04 0.05 ± 4.37  
Male 186.82 ± 12.51 191.27 ± 16.42 4.45 ± 6.07  
Female 210.75 ± 12.46 204.75 ± 14.13  -6.00 ± 5.94  
HDL-C, mg/dL     
GRAPE 46.63 ± 4.78 46.11 ± 4.12 -0.53 ± 0.93 0.490* 
Male 37.27 ± 2.27 38.00 ± 1.73 0.73 ± 1.07 0.474# 
Female 54.75 ± 6.22 56.75 ± 7.46 2.00 ± 1.56 0.558$ 
PLACEBO 
45.53 ± 3.33 46.05 ± 3.84 0.53 ± 1.16 
 
Male 38.82 ± 2.00 38.27 ±180 -0.55 ± 1.64  
Female 59.50 ± 9.40 57.25 ± 8.20 -2.25 ± 1.52  
Non-HDL-C, mg/dL    
GRAPE 150.58 ± 11.18 144.37 ± 10.86 -6.21 ± 4.86 0.458* 
Male 153.45 ± 17.75 144.91 ± 16.34 -8.55 ± 7.70 0.340# 
Female 151.50 ± 12.90 155.25 ± 16.66 3.75 ± 5.55 0.010$ 
PLACEBO 151.37 ± 9.53 150.89 ± 11.18 -.47 ± 4.17  
Male 153.82 ± 13.92 159.00 ± 17.23 5.18 ± 5.74  
Female 154.50 ± 13.10 151.25 ± 14.88 -3.75 ± 3.97  
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* = comparison of GRAPE vs. placebo in entire population, # = comparison of GRAPE vs. placebo in 
male subset, $ = comparison of GRAPE vs. placebo in female subset.  
 
 
Variable Baseline Week 4 Change P-value 
LDL-C, mg/dL     
GRAPE 122.51 ± 8.59 120.32 ± 9.44 -2.19 ± 3.33 0.807* 
Male 119.16 ± 12.97 114.91 ± 12.65 -4.82 ± 4.35 0.405# 
Female 127.10 ± 10.74 128.53 ± 14.63 1.43 ± 5.21 0.049$ 
PLACEBO 125.12 ± 7.61 124.38 ± 9.22 -0.737 ± 3.92  
Male 119.81 ± 10.09 123.13 ± 1349 3.31 ± 5.72  
Female 132.40 ± 11.86 126.00 ± 12.71 -6.30 ± 4.67  
Triglycerides, mg/dL     
GRAPE 140.37 ± 19.78 120.26 ± 12.59 -20.11 ± 11.01 0.147* 
Male 156.45 ± 30.34 121.45 ± 18.05 -35.00 ± 15.79 0.033# 
Female 118.25 ± 21.47 118.63 ± 18.11 0.38 ± 12.11 0.540$ 
PLACEBO 131.26 ± 15.81 132.58 ± 16.21 1.32 ± 7.86  
Male 140.91 ± 23.12 149.36 ± 24.21 8.45 ± 11.57  
Female 118.00 ± 20.80 109.50 ± 17.94 -8.50 ± 9.53  
Glucose, mg/dL     
GRAPE 99.53 ± 2.88 100.74 ± 2.94 1.21 ± 1.63 0.577$ 
Male 99.09 ± 3.89 100.73 ± 3.42 1.64 ± 1.59 0.886# 
Female 100.13 ± 4.56 100.75 ± 5.45 0.63 ± 3.36 0.808* 
PLACEBO 99.32 ± 2.83 99.37 ± 3.01 0.05 ± 1.36  
Male 100.27 ± 4.10 102.27 ± 3.85 2.00 ± 1.87  
Female 98.00 ± 3.93 95.38 ± 4.73 -2.63 ± 1.63  
ALT, U/L     
GRAPE 33.00 ± 3.11 34.63 ± 2.60 1.63 ± 1.46 0.841* 
Male 33.64 ± 3.49 35.00 ± 2.45 1.36 ± 2.02 0.662# 
Female 32.13 ± 5.91 34.13 ± 4.88 2.00 ± 2.24 0.770$ 
PLACEBO 34.32 ± 3.23 35.32 ± 3.54 1.00 ± 1.92  
Male 35.27 ± 3.19 34.55 ± 2.55 -0.73 ± 1.42  
Female 33.00 ± 6.58 36.38 ± 7.97 3.38 ± 4.14  
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Discussion 
The current study has shown that GRAPE, slightly, but significantly reduced BMI in 
subjects with MetS compared to placebo (0.01 ± 0.11 kg/m2 vs. 0.23 ± 0.07 kg/m2, p = 0.048). 
Accompanying this significant reduction in BMI, was a decreasing trend in body weight in the 
GRAPE group (0.03 ± 0.33 kg vs. 0.65 ± 0.21 kg, p = 0.081). In a C57BL/6J mouse model of 
obesity, it has been shown that purified anthocyanins from strawberries and blueberries showed a 
significant decrease in body and fat pad weight (Prior et al., 2014). This group also examined the 
effects of the whole berries, and did not observe significant changes in body or fat pad weight. 
This brings about the question of what other parts of the fruit can positively or negatively impact 
obesity.  
Hollis et al., (2009), published a study in 2009, showing similar results to the current study. 
This study examined the effects of Concord grape juice (CGJ) vs. a polyphenol-free substitute 
juice (SGJ). Anthropometrics remained the same in most aspects of the study, however a 
significant reduction in WC and body weight in the CGJ group was seen. This study was 12 weeks, 
three times the length of the current intervention. At week six of this intervention these effects of 
CGJ had not yet become apparent. Many studies have been conducted on resveratrol, a common 
grape polyphenol. In 3T3-L1 pre-adipocytes it is observed across many studies that PPARγ, 
C/EBPα, SREBP-1c mRNA and protein expression is decreased (Kwon et al., 2012, Chen et al., 
2011, Rayalam et al., 2008, Kang et al., 2012). The result of reduction in such mRNA/ protein 
expression was decreased adipogenesis. In Sprague-Dawley rats, it has been shown that resveratrol 
reduces expression of heparin releasable lipoprotein lipase (HR-LPL), which is the active form of 
this enzyme (Alberdi et al., 2011). When LPL and PPARγ (the transcriptional factor for LPL) were 
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measured, no changes were seen. This suggested a post-translational modification of LPL which 
led to a reduction in uptake of TG in this particular study. 
Other clinical studied on dried fruits (including freeze-dried grapes and raisins) have 
showed minimal effects on plasma lipids. Raisins have shown no impact TC, LDL-C, and TG in 
studies that included men and women (Puglisi et al., 2008, Anderson et al., 2014, Kanellos et al., 
2014). Figs have shown no impact on HDL-C, LDL-C, or TG; but increased TC in men and women 
with elevated LDL-C (Peterson et al., 2011). Freeze-dried grapes showed no changes in plasma 
lipids in a study that included men with MetS at a dose of 46 g/day (Barona et al., 2012). Freeze-
dried grape powder has been shown to decrease LDL-C and TG in pre- and post-menopausal 
women at a dose of 36 g/day (Zunino et al., 2014). Taking these results into account, along with 
the results of the current study (60 g/day), it may be reasonable to theorize a sex-related dose 
dependency may be responsible for the changes observed in the literature. In males, 46 g/day 
showed no improvement in lipoprotein profiles. When the dose was increased to 60 g/day, a 
significant reduction in TG was observed. In females, a 36 g/day dose showed improvements in 
the lipoprotein profile, regardless of menopausal status. When the dosage was increased to 46 
g/day in another study, these improvements were no longer seen. The current study examined 60 
g/day of GRAPE supplementation, and saw a significant increase in LDL-C and TC, respectively. 
This seems to suggest that there is a sex-dependent mechanism, with dose-dependency, that 
contributes to the results seen. 
  
Page 32 of 47 
Page 1 of 47 
 
Chapter 3: Effects of GRAPE on Oxidative 
Stress, Inflammation, and Insulin Resistance 
in Adults with Metabolic Syndrome 
 
Introduction 
 Throughout the world, CVD claimed 17.5 million lives in 2012, amounting to 30% of total 
deaths. Another chronic condition of concern is T2DM. Recent research estimates 9.3% of 
individuals in the United States are afflicted with T2DM, and it is frequently listed as a cause of 
death (American Diabetes Association, 2017). Interestingly, some of the identified risk factors for 
CVD overlap with those of T2DM, which has led to the recognition of MetS (National Institutes 
of Health, National Heart, Lung, and Blood Institute, 2016).  Metabolic syndrome is a constellation 
of symptoms that together, increases the risk for development of T2DM and CVD. 
In the excess central adiposity characteristic of MetS, a state of high plasma FFA or TG 
may be present. The excess may be redirected to non-adipose tissues. Hepatic uptake of FFA is 
unregulated. If circulating levels of FFA are high, the liver will take them into its cells (Malhi and 
Gores, 2008). In the fatty liver, circulating FFA can activate many intracellular responses such as: 
C-jun N-terninal kinase (JNK) activation, toll-like receptor (TLR) activation, and endoplasmic 
reticulum (ER) stress. The downstream result of these activations is insulin resistance (Shoelson, 
2006). Additionally, the activity of TNF-α increases the release of FFA from adipocytes and blocks 
the synthesis of adiponectin, which sensitizes adipose tissue to insulin. Tumor necrosis factor-α 
also can activate NF-κB signal transduction, leading to the production of cellular adhesion 
molecules, and an inflammatory state in the adipocyte (Fernandez-Sanchez et al., 2011). It can 
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also stimulate the expression of IL-6 and MCP-1 (Kern et al., 2001). These molecules attract 
inflammatory cells to the afflicted area and generate a larger inflammatory response. 
 Inflammation is not the sole contributor to insulin resistance. Oxidative stress can result 
in the dysfunction of insulin-related pathways (Keane et al., 2015). Excessive generation of ROS 
can lead to the damage of DNA, protein, and lipid membranes. Oxidative stress via ROS can be 
the result of over nutrition in the form of high glucose and lipid diets (Keane et al., 2015). This 
over nutrition can lead to the dysfunction of the electron transport chain, which produces increased 
ROS. Another pathway that ROS may be generated is via superoxide dismutase. Superoxide can 
be converted to H2O2, which is much more stable. However, H2O2 itself can react with Fe
2+
 to 
produce a highly reactive hydroxyl radical (OH•) (Keane et al., 2015). The consequences of all 
this damage is ultimately cell death and an inflammatory response. 
Insulin resistance, inflammation, and oxidative stress are states commonly associated with 
MetS however, MetS is preventable by lifestyle interventions such as smoking cessation, 
increasing exercise, or modifying diet (National Institutes of Health, National Heart, Lung, and 
Blood Institute, 2016). Data has shown that increased consumption of fruit and vegetables is 
correlated with reduced risk for all-cause mortality and CVD (Wang et al., 2014). This is 
hypothesized to be linked with bioactive food components. The bioactive components can include: 
vitamin C, vitamin E, carotenoids, and polyphenols (Perez-Jimenez and Saura-Calixto, 2008). 
Polyphenols have garnered great interest in research due to their abundance in the human diet, as 
well as antioxidant properties (Manach, et al., 2004). One whole food that is rich in polyphenols 
is the grape (Vitis vinifera). In previous research, the effectiveness of grape seed, skin, stem, and 
extracts on CVD risk have all been studied (Perez-Jimenez and Saura-Calixto, 2008). However, 
the consumption of whole grapes as a dietary intervention has not been fully evaluated 
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(Mozaffarian et al., 2015). It is our hypothesis that ingestion of whole grapes will positively impact 
markers of inflammation, oxidative stress, and insulin resistance when compared to a placebo. 
Materials and Methods 
Plasma Insulin and HOMA-IR 
Plasma insulin was measured using a Luminex/xMAP magnetic bead-based multiplexing 
assays using MAGPIX instrumentation (EMD Millipore, Billerica, MA). Samples from baseline 
and end-point for each arm were run simultaneously to minimize variance. Insulin resistance was 
calculated via the homeostatic assay for insulin resistance (HOMA-IR) using the formula 
established by Matthews et al. (1985); HOMA-IR =  [
glucose (nmol/L)∗ insulin µU/mL)
22.5
 ]. 
Plasma Inflammatory Markers 
Serum inflammatory markers were measured using a Luminex/xMAP magnetic bead-
based multiplexing assays using MAGPIX instrumentation (EMD Millipore, Billerica, MA). 
Analytes measured include: IL1β, IL-6, MCP-1, and TNF-α. Samples from baseline and end-point 
for each arm were run simultaneously to minimize variance. 
Serum TBARS 
Malondialdehyde (MDA) is a compound formed when lipids in the body become oxidized. 
Thiobarbituric acid (TBA) reacts with MDA to form a compound (TBA-MDA) that will fluoresce 
at 532nm. The fluorescence measure of this reaction is one of the most common procedures to 
quantify lipid peroxidation (Draper et al., 1993).  
Serum lipid peroxidation products were assessed by thiobarbituric acid reactive substances 
(TBARS) assay (Farrell et al. 2015). Briefly, 50 µL of samples were added to a 1.5 mL tube. Non-
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lipid TBARS were precipitated out using 100 µL of ice-cold 10% TCA solution. Samples were 
then incubated on ice for 15 minutes. Next, the samples were centrifuged at 2200 x g for 15 minutes 
at 4°C. Following centrifugation, 100 µL of supernatant was transferred to fresh tubes, and 0.67% 
TBA (w/v) was added. The solution was then boiled for 10 minutes at 95°C and subsequently cool 
on ice for an additional 10 minutes. A UV/vis fluorescence microplate was loaded 75 µL of 
standards/ samples. Absorbance was read at 530 nm and plotted against an MDA standard. TBARS 
are expressed in µM of MDA equivalents. 
Serum AOPPs 
Advanced oxidation protein products (AOPP) are a novel marker of protein oxidation in 
plasma, primarily composed of altered albumins (Witko-Sarsat et al., 1996).  Modifications to the 
albumin-lysine residues by myeloperoxidase product hypochlorous acid can affect the interaction 
with SR-B1 (Marsche et al., 2009) The interference with SR-B1 could impair reverse cholesterol 
transport, thus increasing risk for CVD. It is known that serum TG can interfere with the AOPP 
assay in highly lipemic samples (Anderstam et al., 2008).  
Plasma was depleted of apoB-containing lipoproteins via dextran sulfate/Mg2+ method. 
Then, 200 μL of 5-fold diluted plasm or chloramine-T standards (0–100 μmol/L) were mixed with 
20 μL of glacial acetic acid and 10 μL of 1.16 M potassium iodide solution in a 96-well plate. The 
plate was mixed on a clinical rotator for one minute and absorbance read at 340 nm with a 
spectrophotometer. AOPP concentrations are expressed in μmol/L of chloramine-T equivalents.  
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STATISTICAL ANALYSIS 
Differences between end-points of groups were evaluated by independent t tests 
(significance = p < 0.05). Two-way repeated measures ANOVA was used to determine the effect 
of the intervention for variables with baseline measures, with the within subject variables as 
treatment (tests GRAPE vs. placebo effect) and between subjects-variable as sequence order (tests 
carryover effect). All statistical analysis was done using IBM SPSS Statistics software. Data are 
reported as mean ± SEM.  
Results 
EFFECTS OF GRAPE ON PLASMA MARKERS OF OXIDATIVE STRESS 
 Using two-way ANOVA, it was determined that no significant differences were present in 
serum markers of oxidative stress. When stratifying for sex, changes were seen the female subset. 
Plasma AOPPs were seen to be trending toward a significant increase compared to placebo (9.50 
± 10.64 μM vs. -14.85 ± 13.06 μM, p = 0.085). Plasma TBARS were significantly increased with 
GRAPE compared to placebo (0.08 ± 0.10 μM vs. -0.11 ± 0.07 μM, p = 0.042).  
  
Page 37 of 47 
Page 1 of 47 
 
Table 3.3.1. Summary of Plasma Markers of Oxidative Stress. n=19, male n=11, female n=8 
Variable Baseline Week 4 Change P-value 
AOPPs, μM   
  
GRAPE 72.90 ± 27.94 87.25 ± 25.92 14.35 ± 24.21 0.148* 
Male 63.71 ± 7.20 81.94 ± 6.42 18.23 ± 6.04 0.799# 
Female 84.39 ± 11.11 93.88 ± 10.23 9.50 ± 10.64 0.085$ 
PLACEBO 80.80 ± 31.05 78.60 ± 37.48 -2.20 ± 36.65  
Male 71.75 ± 9.11 79.68 ± 9.69 7.93 ± 11.04  
Female 92.11 ± 11.25 77.26 ± 16.66 -14.85 ± 13.06  
TBARS, μM     
GRAPE 0.43 ± 0.20 0.53 ± 0.30 0.10 ± 0.32 0.194* 
Male 0.42 ± 0.07 0.54 ± 0.11 0.12 ± 0.11 0.454# 
Female 0.44 ± 0.07 0.52 ± 0.08 0.08 ± 0.10 0.042$ 
PLACEBO 
0.48 ± 0.24 0.45 ± 0.20 -0.03 ± .28  
Male 0.41 ± 0.06 0.44 ± 0.06 0.03 ± 0.10  
Female 0.57 ± 0.10 0.46 ± 0.08 -0.11 ± 0.07  
* = comparison of GRAPE vs. placebo in entire population, # = comparison of GRAPE vs. placebo in 
male subset, $ = comparison of GRAPE vs. placebo in female subset. 
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EFFECTS OF GRAPE ON PLASMA MARKERS OF INSULIN RESISTANCE 
 Using a paired samples t test, it was determined that no significant differences were present 
in plasma insulin or HOMA-IR score. When stratifying for sex, it was seen that GRAPE 
significantly increased plasma insulin (9.82 ± 3.94 pmol/L, p = 0.042) and HOMA-IR Score (0.40 
± 0.16, p = 0.043) in the female subset. 
Table 3.3.2. Summary of Plasma Insulin Resistance Markers. n=19, male n=11, female n=8 
Variable Endpoint GRAPE vs. PLACEBO P-value 
Plasma Insulin, pmol/L  
  
GRAPE 72.71 ± 12.54 1.03 ± 6.38 0.874* 
Male 80.82 ± 12.20 -9.64 ± 9.12 0.317# 
Female 63.38 ± 10.76  9.82 ± 3.94  0.042$ 
PLACEBO 73.74 ± 8.33 
 
 
Male 90.45 ± 19.24   
Female 53.56 ± 8.42   
HOMA-IR Score    
GRAPE 3.13 ± 0.43 0.03 ± 0.27 0.917* 
Male 3.56 ± 0.64 -0.34 ± 0.41 0.419# 
Female 2.58 ± 0.49 0.40 ± 0.16 0.043$ 
PLACEBO 3.10 ± 0.59   
Male 3.90 ± 0.92   
Female 2.18 ± 0.39   
* = comparison of GRAPE vs. placebo in entire population, # = comparison of GRAPE vs. placebo in 
male subset, $ = comparison of GRAPE vs. placebo in female subset. 
EFFECTS OF GRAPE ON PRO-INFLAMMATORY CYTOKINES 
 Using a paired samples t test, it was determined that no significant differences were present 
in pro-inflammatory cytokines. However, TNF-α was trending toward a decrease when comparing 
GRAPE to placebo (-0.42 ± 0.23 pg/mL). When stratifying for sex, no significance was shown. 
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Table 3.3.3. Summary of Pro-Inflammatory Cytokines. n=19, male n=11, female n=8 
Variable Endpoint GRAPE vs. PLACEBO P-value 
TNFα, pg/mL  
  
GRAPE 4.56 ± 0.37 -0.42 ± 0.23 0.081* 
Male 4.79 ± 0.47 -0.21 ± 0.23 0.397# 
Female 4.40 ± 0.63 -0.56 ± 0.46 0.283$ 
PLACEBO 4.98 ± 0.52   
Male 4.99 ± 0.55   
Female 4.95 ± 1.01   
MCP-1, pg/mL    
GRAPE 151.56 ± 8.83 -9.06 ± 5.90 0.142* 
Male 156.91 ± 11.42 -5.00 ± 9.41 0.606# 
Female 160.92 ± 11.06 -7.03 ± 7.68  0.390$ 
PLACEBO 
160.62 ± 10.40   
Male 161.92 ± 14.10   
Female 167.95 ± 11.59   
IL-6, pg/mL    
GRAPE 3.65 ± 0.65 -0.21 ± 0.63 0.742* 
Male 3.32 ± 0.70 -0.58 ± 1.05 0.590# 
Female 3.94 ± 1.30 0.20 ± 0.48 0.689$ 
PLACEBO 3.86 ± 0.96   
Male 3.90 ± 1.56   
Female 3.74 ± 0.97   
* = comparison of GRAPE vs. placebo in entire population, # = comparison of GRAPE vs. placebo in 
male subset, $ = comparison of GRAPE vs. placebo in female subset. 
Discussion 
 After the 4-week intervention, no effects were seen on oxidative stress markers, plasma 
insulin, HOMA-IR, or pro-inflammatory cytokines with GRAPE ingestion. Zern et al. (2005) 
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assessed the effects of GRAPE on a female population. The results of that study showed a 
significant decrease in TNF-α and no change in IL-6. In the current study both TNF-α and IL-6 
were not significantly reduced by GRAPE when compared to placebo. Hollis et al. (2009) assessed 
the effect of CGJ on insulin compared to a placebo. In this study, over a 12-week intervention, 
insulin showed no significant change. Glucose also showed no significant change. It follows that 
HOMA-IR would also remain unchanged. In a large review, Wang et al. (2013), examined novel 
insights of dietary polyphenols in relation to obesity. It was observed that animal studies showed 
promising results in relation to oxidative stress, however these data did not translate to human 
studies. 
It has been shown previously that polyphenols can be used to induce a pro-oxidative and 
pro-inflammatory state (Lee et al, 2006). The results of the current study, in combination with 
previous literature suggest that 60 g/day of GRAPE may induce a pro-oxidative and pro-
inflammatory state in females. Results in females showed a significant increase in plasma TBARS, 
plasma insulin, and HOMA-IR; as well as a trend in increasing AOPPs. The increase in markers 
of oxidative stress may be a result of increased oxidation due to GRAPE directly, which may lead 
to further insulin resistance in tissues such as adipose and muscle. This further insulin resistance 
may then account for the increase in plasma insulin and HOMA. An alternative hypothesis relates 
to the ability of polyphenols to stimulate insulin secretion from pancreatic β-cells (Dall’Asta et al., 
2015). In this instance, polyphenols may have increased insulin secretion from pancreatic β-cells, 
leading to the increase in plasma insulin and HOMA-IR in an already moderately insulin-resistant 
population. The increased insulin resistance could have contributed to significant and trending 
increases markers of oxidative stress. 
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Summary and Conclusions 
 It was the objective of this thesis to evaluate the effectiveness of standardized, freeze-dried, 
grape powder on adults with MetS. Subjects were consuming the equivalent of 2.5 cups of fresh 
grapes a day, which contains roughly 200 mg of polyphenols. The placebo did not contain 
polyphenols found in grapes. Subjects entered a randomized, placebo-controlled, crossover 
intervention for 13 weeks. This included a 2-week run-in, 4-week intervention (GRAPE or 
placebo), 3-week washout, and final 4-week intervention (alternate powder).  Subjects did not 
significantly alter their diets when comparing GRAPE and placebo. Aim 1 focused on 
cardiometabolic risk factors. We hypothesized that GRAPE ingestion would improve 
cardiometabolic risk factors. Overall, GRAPE improved BMI significantly, was trending toward 
an improvement in weight, but did not improve WC (surrogate for central obesity). When 
stratifying for sex an improvement was seen in men in TG and pulse. However, when stratifying 
for sex, TC and Non-HDL-C was seen to increase in female subjects with GRAPE ingestion. The 
increase in TC can be accounted for by the increase in Non-HDL-C, since HDL-C remained the 
same. This is the opposite of what was hypothesized. Aim 2 focused on the underlying 
comorbidities of MetS; oxidative stress, inflammation and insulin resistance. It was hypothesized 
that GRAPE would have a positive impact on markers of oxidative stress, inflammation, and 
insulin resistance. Overall, no significance was reached between groups when comparing GRAPE 
to placebo in these categories. When stratifying for sex, the male subset had no significant 
differences in any of these variables. However, the female subset presented significant increases 
in TBARS, plasma insulin, and HOMA-IR with GRAPE ingestion. The significant increase in 
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HOMA-IR can be accounted for by the increase in plasma insulin, since glucose remained the 
same. This was the opposite of what was hypothesized. 
Future Directions 
 Future human research is needed to examine the effects of polyphenols on adipocyte 
regulation. Mechanistic studies have presented evidence that polyphenols can inhibit the growth 
of adipocytes (Kwon et al., 2012, Chen et al., 2011, Rayalam et al., 2008, Kang et al., 2012). 
Animal studies have built the case even stronger with reduced body weight and smaller fat pad 
size (Prior et al., 2014 and Alberdi et al., 2011). Now, the current study suggests that GRAPE 
ingestion has reduced BMI significantly, with a trend in decreasing body weight. Additionally, 
plans to measure HDL functionality and NMR for lipoprotein particle size are planned. This 
research may offer further insight into the effects of GRAPE on the lipoprotein profile of adults 
with MetS.  Future research is also needed to assess sex differences in metabolic dysfunction. The 
current study observed markedly different responses between male and female subsets. Further 
data analysis with these subjects may elucidate the mechanisms responsible. Possible studies 
examining the dose-dependency of GRAPE in men and women could provide more evidence of a 
sex relation. Previous studies that have examined the doses of 36 g/day (Zern et al., 2005) and 46 
g/day (Zunino et al, 2014 and Barona et al., 2012), and the current study show marked differences 
between males and females when consuming these doses of GRAPE. Administering these doses 
to men and women in a randomized, placebo-controlled, crossover design may provide answers to 
questions that have arisen in this area. Measures of lipoprotein particle size, oxidation state, and 
associated apolipoproteins could also elucidate potential mechanisms that account for sex 
differences 
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